Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Novartis Investigative Site, Anjo

Novartis Investigative Site, Nagoya

Novartis Investigative Site, Nishio

Novartis Investigative Site, Akita

Novartis Investigative Site, Fukuoka

Novartis Investigative Site, Fukuoka

Novartis Investigative Site, Fukuoka

Novartis Investigative Site, Kasuga

Novartis Investigative Site, Kitakyushu

Novartis Investigative Site, Kurume

Novartis Investigative Site, Yanagawa

Novartis Investigative Site, Asahikawa

Novartis Investigative Site, Obihiro

Novartis Investigative Site, Sapporo

Novartis Investigative Site, Himeji

Novartis Investigative Site, Kanazawa

Novartis Investigative Site, Takamatsu

Novartis Investigative Site, Kawasaki

Novartis Investigative Site, Yokohama

Novartis Investigative Site, Kochi

Novartis Investigative Site, Kōshi

Novartis Investigative Site, Matsusaka

Novartis Investigative Site, Ueda

Novartis Investigative Site, Osaka

Novartis Investigative Site, Osaka

Novartis Investigative Site, Sayama

Novartis Investigative Site, Takatsuki

Novartis Investigative Site, Toyonaka

Novartis Investigative Site, Kawaguhi-city

Novartis Investigative Site, Hamamatsu

Novartis Investigative Site, Fuchū

Novartis Investigative Site, Meguro City

Novartis Investigative Site, Wakayama

Novartis Investigative Site, Yamagata

Novartis Investigative Site, Ube